NASDAQ:PLRX

Pliant Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy PLRX

*Your capital is at risk

$1.09

+0.0100 (+0.93%)

At Close: Jul 24, 2026

Pliant Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.86. In total, the insiders bought 8.11M and sold 3.14M PLRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.86
● Buy	8.11M shares
● Sell	3.14M shares
76% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Apr 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -64.86. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Cummings Keith Lamont Chief Financial Officer	C-Suite Officer	400 000 Value: $520.0K
Jan 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Kuo Minnie Chief Operating Officer	C-Suite Officer	300 000 Value: $390.0K
Jan 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Cheung Lily Chief Human Resource Officer	Officer	300 000 Value: $390.0K
Jan 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Coulie Bernard President And CEO	CEO / President	1 230 000 Value: $1.60M
Jan 20, 2026 Sell	Common Stock S-Sale	Cummings Keith Lamont Chief Financial Officer	C-Suite Officer	24 002 Value: $30.7K
Jan 20, 2026 Sell	Common Stock S-Sale	Cheung Lily Chief Human Resource Officer	Officer	7 534 Value: $10K
Jan 20, 2026 Sell	Common Stock S-Sale	Coulie Bernard President And CEO	CEO / President	89 375 Value: $114.4K
Jan 20, 2026 Sell	Common Stock S-Sale	Kuo Minnie Chief Operating Officer	C-Suite Officer	6 917 Value: $9K
Dec 10, 2025 Buy	Stock Option (Right to Buy)	Kuo Minnie Chief Operating Officer	C-Suite Officer	40 000 Value: $697.6K
Dec 10, 2025 Buy	Stock Option (Right to Buy)	Kuo Minnie Chief Operating Officer	C-Suite Officer	150 000 Value: $2.43M
Dec 10, 2025 Buy	Common Stock	Kuo Minnie Chief Operating Officer	C-Suite Officer	0 Value: $0
Dec 10, 2025 Buy	Stock Option (Right to Buy)	Kuo Minnie Chief Operating Officer	C-Suite Officer	55 200 Value: $614.9K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Bruhn Suzanne Louise Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Knobil Katharine Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Mccourt Thomas A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Curnutte John T Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Krognes Steve E. Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Cline Darren S Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Pyott David E I Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Huh Hoyoung Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Crowell Gayle A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Crowell Gayle A Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Huh Hoyoung Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Pyott David E I Director	Director	30 000 Value: $48.3K
Jun 05, 2025 Buy	Common Stock (Right to Buy) A-Award	Cline Darren S Director	Director	30 000 Value: $48.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PLIANT THERAPEUTICS INC.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which complet...

Read Full Profile Here